Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 20/20 | 0.65 |
| ▸ | MMP13 | P45452 | 10/20 | 0.65 |
| ▸ | MMP2 | P08253 | 2/20 | 0.63 |
| ▸ | MMP3 | P08254 | 2/20 | 0.63 |
| ▸ | MMP9 | P14780 | 2/20 | 0.63 |
| ▸ | MMP7 | P09237 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | MMP14 | P50281 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091942 | 0.96 | MMP12 (0.69) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3082066 | 0.91 | MMP12 (0.63) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3083176 | 0.89 | MMP12 (0.60) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3088206 | 0.87 | MMP12 (0.67) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3091915 | 0.87 | MMP12 (0.64) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3088851 | 0.87 | MMP12 (0.66) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3078581 | 0.87 | MMP12 (0.69) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL6340424 | 0.85 | MMP12 (0.80) | MMP12MMP13 | |
| SCHEMBL3073409 | 0.84 | MMP12 (0.73) | MMP12MMP13MMP2MMP3MMP9 | |
| SCHEMBL3085080 | 0.83 | MMP12 (0.69) | MMP12MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | claimed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | MMP12 3/4885MMP13 1/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.